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Abstract
Background: This study aimed to assess the role of RNA-dependent adenosine deaminase (ADAR1) in cervical
squamous cell carcinoma occurrence and progression.
Methods: ADAR1 expression levels in stage IA and stage IIA cervical squamous cell carcinoma (group A), cervical
intraepithelial neoplasia (CIN) specimens (group B), as well as normal and inflamed cervical tissue samples (group C)
were assessed by immunohistochemistry. Clinical and pathological data of cervical squamous cell carcinoma
patients undergoing surgery were retrospectively evaluated. Chi-square test, comparative analysis of survival curve,
disease-free survival and COX risk assessment method were used to understand the association of ADAR1 with the
occurrence and progression and prognostic significance of cervical squamous cell carcinoma.
Results: ADAR1 is expressed in the cytoplasm and nuclei. The expression level was high in squamous cell carcinoma
tissues (81.18%), while relatively low in the CIN group (21.56%). And there was no expression in non-cancerous tissues.
The differences between them were statistically significant using P < 0.05 as criterion. One-factor analysis revealed that
ADAR1 was significantly correlated with tumor diameter, horizontal diffusion diameter, vascular invasion, parametrial
invasion, vaginal involvement, and pathologically diagnostic criteria for perineural invasion (PNI). Meanwhile, the overall
survival rate of ADAR1 positive patients was significantly lower compared with that of patients with no ADAR1
expression (P < 0.05). Analysis also showed that disease-free survival time of ADAR1 positive patients was shorter than
that of ADAR1 negative patients, and the difference was significant (P < 0.01). Finally, COX risk assessment showed that
parametrical invasion had independent prognostic factors for overall survival of squamous cell carcinoma.
Conclusions: Results indicated that ADAR1 might play an important role in the occurrence, progression and prognosis
of cervical squamous cancer.
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Background
Cervical carcinoma is the second most common malig-
nant tumor in women around the world, and the first
malignancy affecting females in developing countries. In-
deed, about half a million women are diagnosed yearly
with cervical cancer worldwide [1], with a mortality rate
of 9%. In China, the number of new cases of cervical
squamous cell carcinoma each year is 130,000, which ac-
counts for 28% of newly diagnosed cases globally. And
the mortality rate is 14%, which is higher compared with
that obtained in other developing countries. For a long
time, the studies of cancer mechanism had been greatly
focused on the mechanism of DNA imbalance. Recently,
we found that tumorigenesis might be caused by the
process of RNA transcription, in which RNA editing en-
zyme played an important role. RNA editing is wide-
spread in the evolutionary process [2]. It refers to RNA
modifications and processing after the transcription of
DNA into RNA. The edited RNA molecules may be
translated to completely different proteins compared to
their transcribed DNA sequences, hereby changing the
genetic information [3–7]. Studies have shown that ADAR1
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is a RNA-dependent adenosine deaminase, with highest
expression in tumor cells. It mainly plays a role of RNA
editing to change A into G in chronic myelocytic
leukemia [8–10], thereby changing the normal physio-
logical structures and functions of proteins. In addition,
ADAR1 plays an important role in laryngeal squamous
cell carcinoma, and tends to promote its occurrence
and progression [11]. However, relevant studies on cer-
vical squamous cell carcinoma have not been reported
previously. In this study, The mRNA and protein expres-
sion levels of ADAR1 in cervical squamous cell carcinoma
tissues, as well as their associations with patient prognosis,
were assessed, in order to have a preliminary investigation
of ADAR1’s role in cervical squamous cell carcinoma oc-
currence and progression.
Materials and methods
Patients and clinical data
Tissue samples of patients were collected in Gynecology
Department of Chengdu Women and Children’s Central
Hospital. Between February 2012 and December 2015, 170
tissue samples from patients with stage IA-IIA cervical
squamous cell carcinoma (Group A), 102 tissue specimens
from patients with CIN (51 cases of CINI and and 51 cases
of CIN II-III, respectively, Group B), as well as 31 normal
and inflamed cervical tissue samples (Group C) were col-
lected. Patients with cervical squamous cell carcinoma were
selected according to the following critieria: (1) diagnosed
with stage IA-IIA based on the FIGO (International Feder-
ation of Gynecology and Obstetrics) classification; (2)
treated with radical hysterectomy and pelvic lymphadenec-
tomy, with complete postoperative pathological data; (3)
had complete postoperative follow-up data. All th patients
were between 21–68 years old, with an average age of
48.79 years old. According to the FIGO classification, pa-
tients with stage I and stage IIA squamous cell carcinoma
accounted for 68.24 and 31.76%, respectively. Clinical and
pathological data of hospitalized patients were retrospect-
ively analyzed.
Methods
Measurement and comparison of the expressions of
ADAR1 in cervical squamous cell carcinoma in A, B, and C
groups
Immunohistochemical paraffin sections came from the
Chengdu Women and Children’s Central Hospital, De-
partment of Pathology. All samples were fixed by 10%
formaldehyde, embedded in paraffin, and treated with
HE staining. And pathological results confirmed that to
be cervical squamous cell carcinoma. All patients did not
receive preoperative radiotherapy, chemotherapy and
biotherapy.
ADAR1 rabbit anti-human monoclonal antibody was
bought from abcom Company (Shanghai, China). Goat
anti-mouse/anti-rabbit secondary antibody reagents were
purchased from Guangzhou Shenda Biological Products
Technology Co., Ltd (Guangzhou, China). Procedures
exactly followed the manufactures’ instructions:a) Par-
affin section was baked at 65 °C for 3 h, immersed in
xylene to dewax for l0 min for two times, and then
dehydrated using gradient alcohol; b) Paraffin section
was soaked in 3% hydrogen peroxide for l0 min, and
then washed three times using PBS buffer, 3 min for
each time; c) Microwave antigen repair was performed
using 0.4 g citric acid/3 g sodium citrate mixed solution
(1 L.pH 6.0). After 30 min of natural cooling, paraffin
section was washed two times using PBS buffer, 3 min
each time. d) The first antibody (ADAR1 rabbit anti-
human monoclonal antibody) was added and then paraffin
was placed in a humid chamber incubator at 37 °C for
60 min, following with 3 times of wash using PBS buffer; e)
The secondary antibody, i.e. goat anti-mouse/anti-rabbit,
was added and then paraffin was incubated at room
temperature for 30 min before PBS buffer washing for 3
times; f) DAB staining at room temperature for 5 min, and
then washed using tap water for 15–20 min; nuclei staining
using hematoxylin for 2–3 min, and then washed using tap
water for half an hour; g) 85% alcohol, 90% alcohol, 95%
Ethanol, pure ethanol wash for 5 min × 1 times, xylene
wash for 5 min × 2 times. After all of these steps, check
the paraffin using microscope. By the way, we set positive
control and negative control: normal cervical tissue as
a negative control with PBS solution instead of primary
antibody; known esophageal squamous cell carcinoma
as ADAR1 positive control.
Immunohistochemistry was used to detect whether
Pathologically diagnostic criteria for perineural invasion
(PNI) was expressed in cervical squamous cell carcin-
oma. Pathologically diagnostic criteria for perineural in-
vasion (PNI) refers to a focal invasion and metastasis
phenomenon, with tumor cells entering any layer of epi-
neurium, perineurium or endoneurium along nerves fi-
bers or around the nerves, or aggregating and wrapping
the nerves (≥33% of nerve circumference) as well as ex-
tending along them [12].
Sample collection methods were the same as above,
with the only difference was to use S-100 rabbit anti-
human monoclonal antibody instead (purchased from
Guangzhou Shenda Biological Products Technology Co.,
Ltd, Guangzhou, China).
Statistical analysis of association of ADAR1 with clinical
pathology of cervical squamous cell carcinoma
According to FIGO staging of cervical pathology indica-
tors in combination with clinical practice, we chose 15
factors to describe the progression of cervical squamous
cancer, including menopause, motherhood, clinical stage,
keratosis, tumor size, horizontal diffusion distance, stromal
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invasion, histological grade, vascular invasion, parametrial
margin, parametrial invasion, vaginal involvement, lymph
node metastasis, HPV infection, and perineural invasion.
They were compared with ADAR1 expression to explore
the association of ADAR1 with progress of cervical squa-
mous cancer. Clinical and pathological data of group A
undergoing surgery were retrospectively evaluated, using
chi-square test to verify the association of ADAR1 with the
occurrence and progression of cervical squamous cell car-
cinoma. Comparative analysis of survival curve, disease-free
survival and COX risk assessment method were performed
to verify the prognostic significance of ADAR1 in cervical
squamous cell carcinoma.
Follow-up
Mainly, patients with cervical squamous cell carcinoma
were followed-up by telephone, mails or postoperative
visits, from pathological diagnosis to December 2015.
Follow-up lasted for 1–47 months, with an average
follow-up time of 30.4 months.
Immunohistochemical assessment
Positive signals appeared as brown staining in the nuclei
and cytoplasm and percentage of positive cells/total cell
count is used to measure the expression level of ADAR1.
With the normal squamous epithelium as a reference,
positive ADAR1 expression was indicated by a higher
expression, and negative expression, refers to weaker or
comparable expression levels, compared with the amounts
obtained for the corresponding squamous epithelium
specimens. The following scales were used for staining de-
grees: (−), only basal cells stained, with positive cell rate
<5%; (+), focal lesion stained, with positive cell rate ran-
ging from 5 to 30%; (++), extensive staining with positive
cell rate of 31- 60%; (+++), diffused staining with positive
cell rate greater than 60%. Escaping slices or those with
very small numbers of tumor cells (cell count < 200) were
considered ineffective (18 slices).
Statistical analysis
Statistical analyses were performed using the SPSS 19.0
software. One-factor analysis of categorical variables was
conducted with chi-square test; survival curves were
generated by the Kaplan-Meier method. The parameters
of statistical significance from univariate chi-square test
were included in the COX risk assessment to test
whether ADAR1 was an independent prognostic factor
for overall survival in cervical squamous cell carcinoma.
Results
Immunohistochemical data analysis
ADAR1 is expressed in the cytoplasm and nuclei. Negative
and weakly positive signals were considered to be normal
expression, while moderately and strongly positive signals
were considered to be high expression, i.e. positive expres-
sion. Interestingly, the positive rate was found to be
81.18% (140/170) for Group A and 21.56% (22/102) for
Group B, while all Group C cases showed no expression.
In addition, the signal intensity gradually increased with
the lesion severity. The differences among these groups
were statistically significant (p < 0.05).
In ADAR1 positive tissue of cervical squamous cell
carcinoma, the PNI was found around the foci, account-
ing for 14.71% (25/170), which was mainly for the nerve
fibers distributing in the cancer stroma irregularly, and
perineural invasion around the foci was visible with ir-
regular growth of nerve and messy. However, the PNI
expression in ADAR1 negative tissue was negative. The
difference was statistically significant (p < 0.05) (Fig. 1).
Associations of ADAR1 and cervical squamous cell
carcinoma related factors
One-factor analysis data of ADAR1 are shown in Table 1.
A total of 15 factors were analyzed, including menopause,
gravidity, clinical stage, keratinization, tumor diameter,
horizontal diffusion diameter, stroma invasion depth,
histological grade, vascular invasion, parametrial margin,
uterine invasion, vagina involvement, lymph node me-
tastasis, HPV infection, and PNI. Interestingly, tumor
diameter, horizontal diffusion diameter, vagina involve-
ment, vascular invasion, uterine invasion and PNI were
significantly associated with ADAR1 (p < 0.05), as high-risk
factors affecting ADAR1 expression. Besides uterine inva-
sion which had a p < 0.05, the remaining factors showed
p < 0.01, indicating statistical significance (Table 1).
Effect of ADAR1expression in cervical carcinoma
prognosis
Overall survival times of ADAR1 positive and negative
patients were 38.25 ± 1.3 and 45.46 ± 0.86 months, respect-
ively, with a significant difference of p < 0.05 (χ2 = 5.101,
p = 0.024) (Fig. 2). The overall disease-free survival times
were 39.048 ± 1.118 months. The disease-free survival
times of ADAR1 negative and positive patients were
45.458 ± 0.863 and 34.877 ± 1.408 months, respectively,
with a significant difference (χ2 = 12.925, p = 0.000) (Fig. 3).
From overall survival curve, we could see that the 1-year
and 2 year survival rates for ADAR1 negative group were
100 and 93.8%, respectively; while the 1 year and two sur-
vival rates for ADAR1 positive group were 82.1 and 81.2%,
respectively. From disease-free survival curve, we could
see that 1-year and 2 year survival rates for ADAR1 nega-
tive group were both 100%; the 1-year and 2 year disease-
free survival rates for ADAR1 positive group were 80.5
and 70.6%, respectively. Taken together, our data suggest
that ADAR1 positive patients have worse prognosis. To
further study the effect of ADAR1 positive expression on
overall survival rate of cervical squamous cell carcinoma,
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we used multivariate COX proportional hazard model,
and it is showed that parametrial invasion for overall sur-
vival of ADAR1 positive cervical squamous cell carcinoma
had an independent prognostic factor with statistical sig-
nificance (Table 2).
Discussion
ADAR1, also known as RNA editase, has attracted in-
creasing attention in recent years. Athanasiadis et al.
[13] found that ADAR1 had anti-viral and anti-tumor
effect, which was due to the fact that ADAR has a Z-
DNA-binding domain, zalpha, differing with other
members of the ADAR family. The Z-DNA-binding do-
main could bind to the CPG sequence with left-handed
helical structure with a high affinity and specificity.
Once bound, it is associated with interferon response,
leading to the anti-tumor effect. On the other hand, its
erroneous editing or absence of editing may be closely
associated with the occurrence of tumors. The possible
mechanism may be the alteration of proteins involved in
important pathways, thereby leading to tumor occurrence
and progression. Leilei et al. [14] found by transcriptome
sequencing that ADAR1 with A-to-I RNA editing might be
a potential driver in the pathogenesis of human cancer, es-
pecially liver cancer. Jochen et al. [15] found that ADAR1
editing for nuclear adenosine of nerve tissue was crucial for
embryonic development of mouse liver. They generated
inducible ADAR1 interference in mice and found that
ADAR1 played an important role in the maintenance of
adult hematopoietic stem cells (HSC) and the inhib-
ition of interferon signaling pathway. The interferon
signaling pathway can protect many pathological pro-
cesses of the body mainly by downregulating the activation
of harmful effect on interferon, avoiding chronic inflam-
mation, autoimmune diseases and cancer [16, 17]. It is
also known that ADAR1 shows different expression levels
in cancer tissues such as laryngeal cancer, bladder cancer,
and hematologic malignancies, as well as different stages
of tumor progression. However, the molecular mecha-
nisms underlying its effects are largely unclear, with
no report linking ADAR1 to cervical squamous cell
carcinoma.
Fig. 1 Immunohistochemistry (IHC) data showing ADAR1 expression levels in normal cervical, CIN, and cervical squamous cancer tissue specimens.
a Normal squamous epithelium (IHC × 200); b Uterine neck CIN III (IHC × 200); c Cervical keratinizing squamous cell carcinoma (IHC × 200);
d Cervicalnon-keratinizing squamous cell carcinoma (IHC × 200). e Perineural invasion exhibited messy and irregular next to cervical squamous
cell carcinoma lesion (IHC × 200)
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Table 1 One-factor analysis of ADAR1
Characteristics Case (n = 170) Negative Positive P
Menopause 0.144
Yes 68 16(38.23%) 52(76.47%)
No 102 15(14.71%) 87(85.29%)
Gravidity 0.212
< 3 36 4(11.11%) 32(88.89%)
≥ 3 134 27(20.15%) 107(79.85%)
Clinical stage 0.224
I 116 24(20.69%) 92(79.31%)
IIA 54 7(12.96%) 47(87.04%)
Tumor diameter 0.000**
≤ 4 cm 96 27(28.13%) 69(71.88%)
> 4 cm 74 4(5.41%) 70(94.59%)
Keratinization 0.079
Yes 90 12(13.33%) 78(86.67%)
No 80 19(23.75%) 61(76.25%)
Horizontal diffusion diameter 0.000**
≤ 4 cm 102 28(27.45%) 74(72.55%)
> 4 cm 68 3(4.41%) 65(95.59%)
Stroma invasion 0.612
Superficial stroma 8 2(25.00%) 6(75.00%)
Deep stroma 162 29(17.90%) 133(82.10%)
Vascular invasion 0.008*
Negative 36 12(33.33%) 24(66.67%)
Positive 134 19(14.18%) 115(85.82%)
Lymph node metastasis 0.076
Negative 54 14(25.93%) 40(74.07%)
Positive 116 17(88.73%) 99(85.34%)
Parametrial invasion 0.023*
Negative 126 28(22.22%) 98(77.78%)
Positive 44 3(6.82%) 41(93.18%)
Parametrial margin 0.855
Negative 152 28(18.42%) 124(81.58%)
Positive 18 3(16.67%) 15(83.33%)
Vagina margin 0.001**
Negative 80 23(28.75%) 57(71.25%)
Positive 90 8(88.89%) 82(91.11%)
Histological grade 0.318
G1 30 6(20.00%) 24(80.00%)
G2 52 6(11.54%) 46(88.46%)
G3 88 19(21.59%) 69(78.41%)
HPV infection 0.955
Negative 16 3(18.75%) 13(81.25%)
Positive 154 28(18.18%) 126(81.82%)
PNI 0.011*
Negative 31 31(100.00%) 0(0.00%)
Positive 139 114(82.01%) 25(17.99%)
*p < 0.05, **p < 0.01
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Fig. 2 Overall survival curve of patients with ADAR1 positive and ADAR1 negative cervical squamous cell carcinoma. Survival time of ADAR1
positive group was 38.252 ± 1. 301 month, survival time of ADAR1 negative group was 45.458 ± 0. 863 months. The difference was statistically
significant (χ2 = 5.101, p = 0.024). 0 = ADAR1 negative group; 1 = ADAR1 positive group
Fig. 3 Disease-free survival curve of patients with ADAR1 positive and ADAR1 negative cervical squamous cell carcinoma. Overall disease-free
survival time was 39.048 ± 1.118 months. Disease-free survival time of ADAR1 negative group was 45.458 ± 0.863 months, disease-free survival time
of ADAR1 positive group was 34.877 ± 1.408. The difference was statistically significant (χ2 = 12.925, p < 0.001). 0 = ADAR1 negative group;
1 = ADAR1positive group
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ADAR1 expression in different cervical tissues
As shown above, we found that ADAR1 was highly
expressed in the cytoplasm and nuclei and its expression
level gradually increased with cervical disease stage. The
close association of ADAR1 with cervical squamous cell
carcinoma, as well as its progress indicates it may play
an oncogenic role in the occurrence and progression of
cervical squamous cell carcinoma. Thus, ADAR1 might
be considered as an oncogene in cervical squamous cell
carcinoma.
Associations of ADAR1 with different clinicopathologic
features of cervical squamous cell carcinoma
A prospective study on extensive hysterectomy for initial
treatment of stage 1B cervical carcinoma conducted by
the [gynecologic oncology group] GOG revealed that
tumor diameter, invasion depth and vascular invasion
are independent prognostic factors [18]. Except this,as
shown above, we found that horizontal diffusion diam-
eter, parametrial invasion, and vagina involvement were
also significantly associated with ADAR1 expression.
Surgery for phase Ib–IIa cervical carcinoma with a
diameter greater than 4 cm is very difficult and prone to
postoperative focal recurrence and distant metastasis
[19]. This is especially true when a large tumor size is
combined with deep myometrial invasion. Based on the
GOG study, it indicates that tumor diameter, invasion
depth and vascular invasion are related to horizontal dif-
fusion diameter, parametrial invasion, and vagina in-
volvement, affecting prognosis. Our findings indicated
an association of ADAR1 with the metastasis, invasion,
and malignancy of cervical squamous cell carcinoma.
However, the mechanism is not clear, which needs for
further study.
Previous studies reported that PNI is a risk factor pre-
dicting tumor recurrence and death, and tumor invasion,
whether to nerve trunks or endings, could increase the
risk of recurrence and decrease survival [20–22].
In this study, we also found that PNI existed in the
foci of ADAR1 positive cervical squamous cell carcin-
oma, indicating the presence of the nerve fibers might
play a role in regulating the progress of cervical squa-
mous cell carcinoma. Furthermore, it was found that
the ADAR1 positive cases were concurrent with PNI
expression, indicating that PNI was associated with
ADAR1 positively. These data suggest that ADAR1 is
an important indicator of prognosis in cervical squamous
cell carcinoma.
Relationship between ADAR1 and cervical squamous cell
carcinoma prognosis
From the overall survival curve, there was difference in
survival rate within 24 months between the ADAR1
positive group and the ADAR1 negative groups, and the
two sets of data tended to balance in 30 months. The
similar results were also found in disease-free survival
curve. From the figure, the recurrence and mortality of
the stage I-IIA patients with cervix squamous cell car-
cinoma in 30 months after surgery were greatly reduced
with stabilized condition. Combined with result of Cox
proportional hazards assessment and the PNI expression
in squamous cell carcinoma, it suggested that ADAR1
expression was not only associated with the metastasis,
invasion, and malignancy of cervical squamous cell
carcinoma but also closely related to the prognosis,
which further confirmed that ADAR1 expression had
guiding significance for prognosis of cervical squamous
cell carcinoma.
Table 2 Multivariate analysis of the predictive value of cervical squamous cell carcinoma overall survival for each variable clinical case
Variables B S.E. Wald df Sig. Exp(B) 95% CIfor EXP (B)
Lower Upper
PNI -.295 .634 .217 1 .641 .744 .215 2.579
Tumor diameter .407 .454 0820 1 .370 .666 .212 2.969
Horizontal diffusion -.231 .673 .118 1 .732 .794 1.183 15.581
Vessel invasion .016 .572 .001 1 .978 1.016 .331 3.115
Parametrial invasion 1.090 .401 7.411 1 .006* 2.976 1.357 6.525
Vagina involvement -.173 .574 .091 1 .763 .841 .273 2.590
Constant -.277 1.039 .071 1 .790 .758
*p < 0.05
PNI pathologically diagnostic criteria for perineural invasion
B coefficient of regression
S.E standard error
Wald Wald Chi-Square
df degree of freedom
sig statistically significant
EXP(B) B coefficient index
95% CI for EXP (B) 95% confidence interval
OR odds ratio
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Conclusion
Our preliminary study demonstrates the increased ex-
pression of ADAR1 is associated with development and
progress of cervical squamous cell carcinoma. However,
further studies are warranted to investigate its under-
lying molecular mechanisms.
Additional file
Additional file 1: Original data of baseline, clinical pathological
diagnosis, prognosis and follow-up for ADAR1 patients. (DOC 825 kb)
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